Approach of Persian medicine to health and disease

Tfazaoli, Vahid; Tavakoli, Ali; Mosaffa-Jahromi, Maryam; Cooley, Kieran; Pasalar, Mehdi

doi:10.1016/j.aimed.2021.07.007

Cited by 9 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to PM sources, an imbalance of the four body humours can lead to disease, such that the dominance of coldness and wetness (phlegm) can cause nervous system diseases like peripheral neuropathy. [ 21 ] On the other hand, consuming medicinal plants with the opposite temperament (hot and dry) can effectively balance the humours and cure the disease. [ 22 ] From this point of view, ajwain has a hot and dry temperament and can help solve peripheral neuropathy symptoms.…”

Section: Discussionmentioning

confidence: 99%

Exploring the Effectiveness of Ajwain Cream in Treating Taxane-induced Peripheral Neuropathy in Cancer Patients: A Pilot, Randomised and Double-blind Clinical Trial

Heydarirad,

Mirzaei,

Gharehgozlou

et al. 2024

IJPC

Self Cite

View full text Add to dashboard Cite

Objectives: Chemotherapy-induced peripheral neuropathy is a common disorder among cancer patients receiving various chemotherapeutic protocols. The present study aimed to explore the feasibility of ajwain (Trachyspermum ammi [L.] Sprague) cream in treating peripheral neuropathy symptoms triggered by taxane chemotherapeutic agents. Materials and Methods: This was a pilot, double-blind, and randomised clinical trial on patients with peripheral neuropathy attributable to chemotherapy with taxane drugs during 2021–2022 in Tehran. Patients received ajwain or placebo cream for four weeks and filled out the chemotherapy-induced peripheral neuropathy assessment tool (CIPNAT) at the start and end finale of the trial. Side effects were also noted. Results: Thirty patients suffering from breast, lung, gastro-intestinal, or prostate cancer were allocated to each of the drug and placebo groups. The mean difference in CIPNAT score between the groups was 0.83, demonstrating the statistical ineffectiveness of the drug compared with the placebo (P = 0.372). The safety profile showed promising outcomes at the end of the trial. Conclusion: Although the effectiveness of ajwain cream was unacceptable in treating chemotherapy-induced peripheral neuropathy symptoms, multicentre controlled trials with ample sample size are mandatory for an all-inclusive inference.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring the Effectiveness of Ajwain Cream in Treating Taxane-induced Peripheral Neuropathy in Cancer Patients: A Pilot, Randomised and Double-blind Clinical Trial

Heydarirad,

Mirzaei,

Gharehgozlou

et al. 2024

IJPC

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a holistic school of medicine, PM has a special approach to treating various diseases. In this approach, treatment is started with dietary instructions and lifestyle modifications, with pharmaceutical prescriptions given only if there is no proper response ( Tafazoli et al, 2022 ). Adherence to PM-based treatments requires initial compliance with nutritional instructions and lifestyle guidelines, which are quite difficult to implement considering the pandemic nature of COVID-19 and its psychological burden on the patient and the patient’s family.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial

Mosaffa-Jahromi,

Molavi Vardanjani,

Fuzimoto

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Background: Gastrointestinal symptoms are prevalent amongst patients with a confirmed diagnosis of COVID-19 and may be associated with an increased risk of disease severity. This trial aimed to evaluate the efficacy and safety of aniseed (Pimpinella anisum L.) powder as an add-on therapy to standard care for treating gastrointestinal symptoms experienced by adults with an acute SARS-CoV-2 infection.Methods: The study was a randomized parallel-group double-blinded placebo-controlled add-on therapy trial. Adults with an acute SARS-CoV-2 infection who did not require hospitalization and reported at least one gastrointestinal symptom in the preceding 48 h were assigned to either the aniseed or placebo group in a 1:4 ratio. All 225 participants (45 in the aniseed group and 180 in the placebo group) were instructed to use 25 g of powdered aniseed or placebo twice daily for 2 weeks. The primary outcomes were the proportion of patients who experienced an improvement of at least one point in the symptom score after adjusting for age group, gender, and time. Backwards stepwise logistic regression was applied to calculate the risk ratios. The clinical symptoms and adverse events were assessed at the beginning, 1 week later, and at the end of the trial (week two).Results: Participants in the aniseed group were significantly more likely to report symptom improvement for abdominal pain [adjusted risk ratio (RR):0.55; 95% confidence interval (CI): 0.46–0.72], anorexia (RR:0.62; 95% CI: 0.47–0.82), and diarrhea (RR:0.19; 95% CI: 0.12–0.30), but not nausea/vomiting (RR:0.87; 95% CI: 0.71–1.08) or bloating (RR:0.87; 95% CI: 0.72–1.05). Two participants in the aniseed group and three participants in the placebo group reported mild to moderate adverse events.Conclusion: This study showed that 2 weeks of aniseed powder containing trans-anethole (87%–94%) may help improve abdominal pain, anorexia, and diarrhea in COVID-19 patients. The findings align with the known biological, multitargeted activity of P. anisum and trans-anethole, which includes inhibiting SARS-CoV-2 along with other anti-infective, anti-inflammatory, antioxidant, hepatoprotective, and anti-dysbiosis properties. Multicenter trials with larger sample sizes and longer follow-up are warranted to confirm these findings.Clinical Trial Registration: Iranian Registry of Clinical Trials (IRCT20120506009651N3).

show abstract

“…Importantly, however, the reported rates of CAM use are affected by the different CAM methods chosen across countries and regions (35). Given the variety of CAM approaches available in Iran as part of traditional Persian medicine, with some administered through lesions (36), it is indeed significant that the only method chosen by people living with HIV in the Fars province is herbal medicines, which do not possess any risk of HIV transmission during the administration. CAM can be a useful approach for people living with HIV to improve wellbeing, stress, anxiety, fear, depression, pain, fatigue, fever, and neuropathy (35, 37-39).…”

Section: Discussionmentioning

confidence: 99%

Complementary and alternative medicine use among people living with HIV in Shiraz, Southern Iran

Mosavat,

Pasalar,

Joulaei

et al. 2023

Front. Public Health

Self Cite

View full text Add to dashboard Cite

BackgroundLiving with HIV requires lifelong care to support engagement with and adherence to antiretroviral therapy. The Middle East and North Africa region provides access to ART, but research is lacking on the lived-experiences of people living with HIV. Globally, complementary and alternative medicine (CAM) is increasingly used by patients who need support alongside receiving medical treatment for chronic conditions. This study aims to examine the frequency and reasons behind the use of CAM, as well as identify its associated factors among people living with HIV in Shiraz, Iran.MethodsIn this cross-sectional study, a total of 320 patients (aged 18–70 years) with a confirmed diagnosis of HIV residing in Fars province and diagnosed between 1999 and 2019 were recruited randomly through their clinical record numbers from five HIV treatment centers. They were surveyed on their quality of life and CAM use via the Short-Form Health Survey questionnaire (SF-36) and a semi-structured survey of “CAM use.” The data analysis for this study involved the use of Chi-squared test, independent t-test, and multiple logistic regression model.ResultsOf 287 patients, 89.22% reported using CAM in the previous year. CAM use was more prevalent among those with a family history of CAM use (94.3% vs. 81.8%, p = 0.023). Frequent reasons for using CAM were reported to be sexual dysfunction (32.4%), depression (28.3%), thirstiness (23.3%), and nausea (17.5%). Quality of life, as measured via the SF-36 questionnaire in all its 8 sub-domains, did not differ among those who used CAM versus those who did not (61.5 ± 27.6 vs. 58.1 ± 30.9, p = 0.626).ConclusionCAM was used among a majority of people living with HIV in Shiraz, Iran. People who used CAM appeared to experience a similar quality of life relative to those who did not use CAM. Future studies on the modalities of engagement with CAM can improve patient-physician shared decision-making and increase lifelong care options for people living with HIV.

show abstract

Approach of Persian medicine to health and disease

Cited by 9 publications

References 35 publications

Exploring the Effectiveness of Ajwain Cream in Treating Taxane-induced Peripheral Neuropathy in Cancer Patients: A Pilot, Randomised and Double-blind Clinical Trial

Exploring the Effectiveness of Ajwain Cream in Treating Taxane-induced Peripheral Neuropathy in Cancer Patients: A Pilot, Randomised and Double-blind Clinical Trial

Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial

Complementary and alternative medicine use among people living with HIV in Shiraz, Southern Iran

Contact Info

Product

Resources

About